Skip to search formSkip to main contentSkip to account menu

CP 4126

Known as: CP-4126, CP4126 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

CA-101CO-101

Broader (2)

DeoxycytidineGemcitabine Elaidate
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Phase II study of CP-4126, a gemcitabine-lipid conjugate, in patients with advanced pancreatic cancer.
e14674 Background: Uptake of hydrophilic nucleoside analogues into tumor cells is determined by membrane transporter expression… 
2010
2010
Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumors.
e13078 Background: CP-4126 (gemcitabine-5′-elaidic acid ester) is a novel nucleoside analogue with preclinical antitumor activity… 
Review
2010
Review
2010
FDA Pipeline preview, February 2010 (Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126)
Recent FDA action (through February 2010) related to Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone… 
2009
2009
DOI 10.1007/s10637-009-9377-7 PRECLINICAL STUDIES
  • 2009
  • Corpus ID: 218612792
2007
2007
Proffered papers and posters
The deoxynucleoside analogues cytarabine (Ara-C) and gemcitabine (dFdC) are drugs commonly used in the treatment of cancer. Due…